The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's experimental gene therapy to treat ...

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys.

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

This is a developing story and will be updated as more information becomes available. | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...

The drastic cost-cutting move followa the deaths of two teenagers that forced the company to restrict usage of its gene ...

Sarepta Therapeutics faces a challenging period as it navigates recent setbacks with its groundbreaking gene therapy, leading ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

Boyang Wang on Targeting Underfunded Longevity Projects SINGAPORE, SG / ACCESS Newswire / July 16, 2025 / Immortal Dragons, a ...

The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January. This is the ...